Daniel FischerFounder and CEO at Tevard Biosciences
Daniel Fischer is Founder and CEO of Tevard Biosciences, a company he co-founded with Harvey Lodish and Warren Lammert to develop novel gene therapy approaches to cure Dravet Syndrome and other rare diseases with high unmet need. The company has developed two novel platforms to treat rare diseases not amenable to traditional gene therapy approaches. The companies scientific team includes: Harvey Lodish, Bob Langer, David Liu, Orrin Devinsky, Ben Deverman, and Jeff Coller, among others.
Daniel is also Regional Director (ILP) at the Massachusetts Institute of Technology (MIT). At MIT Daniel works with industry, academic researchers, and startups in advancing the state-of-the-art in multiple disciplines, including: AI/machine learning, new materials, nanotechnology, IoT, and innovation management.
Formerly Daniel was the Director of the Epilepsy Therapy Project of the Epilepsy Foundation where he drove the development of new therapies for the epilepsies in partnership with industry and academia, and envisioned novel programs including the Epilepsy Innovation Institute (Ei2).
Daniel was President and CEO of Intellimedix a company he founded to repurpose FDA approved drugs for Dravet Syndrome and other rare diseases using high-throughput in silico and zebrafish screening.
Prior to entering the biotech sector Daniel was a management consultant with several top-tier consultancies including A.T. Kearney, Arthur D. Little, and Zyman Group (with ex-Coca Cola CMO, Sergio Zyman). Daniel lives in Newton, MA with his wife Karina and 4 children: Jonathan, David, Nicole and Natasha.